S-5488-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Chris Van Hollen (D-MD)
What it does
The bill would require the HHS Secretary to award grants to groups of providers (a hospital, clinic or university health center "hub," at least one "spoke," and a community-based nonprofit) to set up sickle cell disease treatment centers. It would also create a National Sickle Cell Disease Coordinating Center and a CDC data collection program, and require a Federal Register request for information within 180 days and reports to Congress. It would authorize "such sums as may be necessary" each year starting in fiscal year 2027, with set percentages for hubs, community groups, the coordinating center and CDC data work, and the funds would supplement, not replace, existing HHS activities. Actual funding would depend on later appropriations.
Who benefits
People with sickle cell disease or related hemoglobinopathies, including children moving to adult care, who could gain coordinated care, telehealth, transportation help and insurance assistance. Hospitals, clinics, federally qualified health centers and community nonprofits that win grants. Historically Black colleges and minority-serving institutions with health programs, which may receive priority. Rural patients and regions with high disease prevalence, which are named in the grant priorities. Researchers and public health officials who would gain better national data.
Who is hurt
Federal taxpayers, who would bear an open-ended authorization of "such sums as may be necessary" if Congress appropriates it. Patients with other rare or chronic diseases and competing HHS programs, which may face tradeoffs if appropriations are limited. Applicants that cannot assemble a hub, spoke and nonprofit partnership, such as small or isolated providers. Grantees would face new data-reporting, guideline-compliance and administrative burdens. HHS and CDC would need to absorb new administrative work.
Supporters argue
Supporters argue that sickle cell disease is a serious inherited condition that has historically received less funding and fewer specialized care options than comparable conditions. They contend the hub-and-spoke model extends specialist expertise to underserved and rural areas, links medical care with social supports, and improves national data. They point to the bill's required reporting to Congress as a way to measure outcomes.
Opponents argue
Opponents argue that the bill authorizes unspecified, open-ended spending with no dollar cap or sunset, which weakens congressional budget discipline. They contend that existing HHS, CDC and Medicaid programs already address sickle cell disease and that new layers of grants, coordinating bodies and reporting add administrative cost. They also argue that a disease-specific program creates funding tradeoffs with other conditions that serve similar populations.
Constitutional context
Congress's authority rests on the Taxing and Spending Clause (Art. I, §8, cl. 1), which lets it fund voluntary grants for the general welfare. Because grantees opt in and no state is compelled, the coercion concern from NFIB v. Sebelius (2012) is not clearly implicated.
Checks and balances
The executive branch (HHS and CDC) gains grant-making and program-design discretion, while Congress keeps control through annual appropriations, the required reports to its committees, and oversight of the Secretary's guidelines.
Historical precedent
Congress previously funded sickle cell efforts, such as the Sickle Cell Disease Treatment Demonstration Program and CDC's sickle cell data collection, which this bill references and builds on.